Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
Date:5/8/2012

NEW YORK, May 8, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2012.

At March 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $31.0 million, as compared to $39.5 million at December 31, 2011. 

The net loss for the first quarter ended March 31, 2012 was $9.1 million, or $0.13 per share, compared to a net loss of $6.4 million, or $0.10 per share, for the comparable quarter in 2011, representing an increase in net loss of $2.7 million.  Other research and development expenses, for the first quarter ended March 31, 2012, increased by $2.5 million, as compared to the first quarter of 2011, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs.  The net loss for the first quarter ended March 31, 2012, included $0.6 million of non-cash compensation expense related to equity incentive grants.

On May 4, 2012, the Company executed a License Termination and Technology Transfer Agreement with Aeterna Zentaris GmbH ("Zentaris"), whereby the license agreement for KRX-0401 (perifosine) was terminated, and in exchange for the transfer of the U.S. Investigational New Drug Application, development data, intellectual property and contracts to Zentaris, Keryx shall receive a royalty on future net sales of perifosine in the U.S., Canada and Mexico.  Zentaris has assumed all costs related to the Perifosine program going forward. 

Ron Bentsur, the Company's Chief Executive Officer, said, "Though we were disappointed with the recent negative outcome of the perifosine Phase 3 study in colorect
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 A hernia is condition ... protrudes through the wall of a weak muscle area. Obesity, ... are some of the causes of hernias. There are several ... incisional. An inguinal hernia is when part of the abdominal ... found in the area of the umbilicus. A hiatal hernia ...
(Date:11/26/2014)... 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical company ... infectious diseases, announced today the addition of ... opinion leader in the areas of pneumonia and ... Founder and Chief Executive Officer, Vu ... extensive experience investigating bacterial toxins and key mechanisms ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... NovaRx Corporation announced today the appointment of Norrie ... Chief Operating Officer. Dr. Russell brings to the ... and a long history of success driving innovation in ... leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) ... milestones,achieved in 2008 and preview objectives for 2009 during ... New York City today. , David Smoller, ... discuss the progress and expected potential of the,two companies, ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6
(Date:11/27/2014)... Los Angeles, CA (PRWEB) November 27, 2014 ... are thrilled to be part of Omadox, a feature ... Film Festival, including an award for best ensemble cast. It ... Festival. This is a great start to a successful cinematic ... experimental/sci-fi, black and white movies. If you enjoy experimental mystery, ...
(Date:11/27/2014)... Acapulco, Guerrero (PRWEB) November 27, 2014 ... the time individuals allot to sleep has lessened, ... televisions and laptops, the quality of sleep has ... workers falls asleep on the job (Reference: ... American worker’s productivity index by an incalculable amount, ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows that ... and she wants to lessen its impact. "After showering ... that there needed to be a way to maintain ... use and producible in design variations, the End Scentuous ... throughout the day. It avoids bad odors, as well ...
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... Will Feature Nearly 100 Exhibits, Forums on Health Care ... Health Screenings and Top Musicians***LOS LOBOS TO HEADLINE ENTERTAINMENT***SAN ... largest advocacy organization for people age 50+, today announced ... event to San Antonio on May 15-16. ...
... But it,s unlikely these factors cause the neurological condition, experts ... older mothers and children who have breech deliveries are almost ... researchers report. , The findings confirm those of other studies ... genetic base, researchers say. , "A child with breech ...
... surgeons can agree! There is often disagreement between ... the proper therapy for coronary artery disease (CAD)and ... edition of Deutsches rzteblatt International , an ... cardiac surgeons provides answers to the question of ...
... to attend TCT 2009 (Transcatheter Cardiovascular Therapeutics), the ... TCT gathers leading medical researchers and clinicians from ... latest developments in the field of interventional cardiology ... TCT brings state-of-the-art techniques and training to interventional ...
... National Infant Immunization Week is April 25 - May ... To kick off National Infant Immunization Week, ... for all parents to fully immunize their children against ... preventable diseases such as whooping cough, meningitis and measles ...
... IAC for Electronic ClaimsJACKSONVILLE, Fla., April 27 ... today announced that Insurers Administrative Corporation (IAC) has ... compliant electronic claims. As an Availity client, health ... Availity(R) Health Information Network free of charge.(Logo: ...
Cached Medicine News:Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 2Health News:AARP to Host Cross-Generational 'Life Festival' in San Antonio May 15-16 3Health News:Autism Tied to Older Moms, Breech Birth 2Health News:Autism Tied to Older Moms, Breech Birth 3Health News:Media registration now open for TCT 2009 2Health News:Pennsylvania Secretary of Health Reminds All Parents to 'Be Wise, Immunize Your Children' 2Health News:Insurers Administrative Corporation Joins the Availity Network 2
Wright-Giemsa Stain Solutions...
... For fast, single-solution staining, Hema-Quik ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
... for staining of peripheral blood smears ... stain formulations still in use today. ... of Giemsa stain, although eosinophillic granules ... granules and nuclear chromatin stain a ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: